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This study examined the relation between the risk of
cardiac rupture and the timing of throsbolytic therapy for
acute myocardial infarction. To test the hypothesis that
cardiac rupture is prnented by early thromfaltle therapy
but is promoted by late treatment, randomized controlled
trials; of thrombolylc agents for myocardial infarction were
patient
. A logistic regression model including 58 cases of
cardiac rupture among 1,638 patients front four trials
showed that the odds ratio (trestedlcontra0 of cardiac
rupture was directly correlated with time to treatment (p =
0.01) ; at 7 b, the odds ratio was 0 .4 (95% Confidence limits
0.17 to 0
.93); at 11 h, it was 0.93 10.53 to 1
.60) and at 17 h,
it was 3.21 (1.10 to 10.1).
Analysis of data from the Grapple Itagnno per t Studio
Cardiac rupture is a catastrophic complication that occurs in
3% to 4% of patients admitted to the hospital with acute
myocardial infarction (1,2) and has been found in 38% of
patients at autopsy in clinical trials of thrombolytic agents
(3-18) . Cardiac rupture occurs only after acute tansmural
myocardial necrosis (2,19-21), and because reperfusion lim-
its transmural necrosis (22,23), we postulated that early
thrombolytic therapy would decrease the risk of cardiac
rupture (Fig
. 1). In addition, however, thrombolytic therapy
promotes hemorrhage into the fresh infarction (10.24-33).
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dells Streptoebl ad .eWlahrlu Mfoardlco (G1SS1) trial
independently coWred the relation between time to
thrombolyric therapy aad risk of crdiac rapture (p =
0.03). Analysis of 4,02 deaths In 44,366 Patients dearea-
strated that the odds ratio of death was also directly,
correlated with that le treatment (p = 0.000)
;
at 3 b, the
odds ratio for death was 0
.72 (6.67 to 0.77); at
14 it, it wait
0 .88 (0 .77 to 1 .00) and at 21 b, it was 1 (0.82 to 1,37) .
Thrombollle therapy early other Kate myocardial In-
farction improves survival and decreases the risk of caratrc
capture . We admialstrataa of Irembdytlc therapy also
appears to Improve survlrat but my Increase, the risk of
cardiac rupture.
(j Am Cog Csudiol
1990;16 359-67)
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and because cardiac rupture is caused by dissection of blood
through regions of transmural necrosis (19,20,34-36), we
also hypothesized that [ate thrombolytic therapy would
increase the risk of cardiac rupture (Fig. I).
Thrombolytic therapy during the early hours of myocar-
dial infarction improves survival (3,37-41), and recent data
(38) suggest that later treatment may also improve survival .
The effects of late therapy have been less well defined,
however, and excessive delay may actually be detrimental if
the benefit of therapy is reduced while the risk of therapy
remains the same oreven increases. To evaluate the effect of
the time to treatment on the risk of cardiac rupture and
all-cause mortality, we performed a meta-analysis of ran-
domized controlled trials of thrombolytic therapy for acute
myocardial infarction .
Methods
Reported raadombmd control trials of thrombetytle ther-
apy. The Bibliographic Retrieval Service (BRS) program
accessed reports pub!ished before March l, 1989 and is,
dexed in the MEDLINE Information System (42,43) under
the terms "fibrinolytic agents," "myocardial infarction."
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Figure 1 . Proposed pathogenesis of cardiac rupture as affected by
thrombolytic therapy .
"random," "trials" and "clinical trials." This search was
supplemented with known pertinent references and their
bibliographies . Articles were selected if they reported 1)
randomized controlled trials of thrombolytic agents for acute
myocardial infarction, 2) cardiac rupture or mortality data,
3) the mean time to treatment, and 4) five or more outcome
events. An additional criterion for analysis of the effect of
thrombolysis on cardiac rupture was that autopsies be re-
ported on m50% of the fatalities in the trial because previous
studies (3,44) have shown a poor correlation between clinical
suspicion of cardiac rupwre and autopsy findings .
Statistical methods. The results of these trials were
pooled to estimate the odds ratios of events (cardiac rupture
or death) in treated versus control patients with respect to
time from symptom onset to treatment :
Treated patients Untreated patients
with event without event
Odds unto =
Treatedpatients X Untreated patients'
without event with event
An odds ratio <1.0 implies a reduced risk of an event
after treatment, whereas a value >1 .0 implies greater risk.
The mean time to treatment was defined as either the mean
time to treatment for an entire trial or the midpoint of a time
interval for a subgroup of patients in a trial .
Logistic regression models (45) were used to assess the
relation between the risk
of an event and 1) the treatment
group, 2) the mean time to treatment, and 3) the interaction
between treatment effect and time to treatment
. The latter
term assesses, the degree to which the
treated/control
odds
ratio varies with time
. All groups were weighted by the study
sample size so that, in effect, the mean time, treatment and
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outcome group indicators were duplicated as many times as
there were actual patients in the corresponding class in each
study . By adjusting for treatment, each study served as its
own control, and studies with different patient groups could
be combined in a meaningful way, provided that the random-
ized groups within each trial were comparable . Trials were
also combined by the Mantel-Haenszel method (46,47) into
time interval subgroups for display of odds ratios and their
associated 95% confidence intervals .
Results
Trial selection. From 503 articles reviewed, 42 trials
(4,8-17,37-41,48-76) involving 44,346 patients and 4,692
deaths met criteria for analyzing the effect of the timing of
thrombolytic therapy on mortality. Thirty-two of these trials
(38-41,49-76) were excluded from the analysis of cardiac
rupture because either cause o: death or autopsy data were
not reported; four trials (10,11,14-16,37,77) were excluded
because autopsies were reported on <50% of patients who
died and two trials (17,48) were excluded because only one
or two events were observed
. Thus, four trials (4,8,9,12,13)
involving 1,638 patients and 58 episodes of cardiac rupture
met criteria for analysis of the effect of the timing of
thrombolysis on cardiac rupture (Table 1) .
Timing of thrombalytic therapy and cardiac rupture. In-
travenous streptokinase was the thombolytic agent in all four
trials used to assess the effect of thrombolysis on cardiac
rupture, although the loading dose, total dose and duration
of the infusion differed (Table i) . The mean time to treatment
for the trials ranged free, 9 to 21 h. Baseline characteristics
thought to be risk factors for cardiac rupture, including age
(1,19-21), female gender (1,19,78), lack of previous angina
(19-21,79) or myocardial infarction (2,19-21,79), hyperten-
sion during the acute phase of infarction (19,20,78) and
electrocardiographic evidence of transmural infarction
(21,79,80), were all similarly distributed between treated and
control groups within each trial and among trials where data
were available .
The odds ratio of cardiac rupture increased significantly
(' = 6 .2, p = 0 .013) with delay in the mean time to
treatment (Fig . 2). The regression line crossed an odds ratio
of 1 .0 at 11 h after symptom onset and the 95% confidence
limits associated with this odds ratio were < l .Ofor treatment
begun within the first 7 h, suggesting a beneficial effect of
early treatment on cardiac rupture. Conversely, the 95%
confidence limits for treatment initiated >17 h after symp-
tom onset were > 1 .0, suggesting a detrimental effect of late
therapy on cardiac rupture .
The Gruppo Italiano per to Studio della Streptochinasi
nell'lnfarto Miocardico (GISSI) trial (37,77) did not meet
entry criteria for the primary meta-analysis because autopsy
was performed in only 16% of the 1,386 patients who died in
the hospital, yet the results of this trial merit further study
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because of the Isrge ..^ember of patients randomized . Cardiac
rupture was the cause of death in 58% of autopsy patients in
the GISSI trial . Cardiac rupture was documented in 1
.1% of
control patients at a fairly constant rate regardless of time to
entry into the study . However, among those treated with 1 .5
million U of intravenous streptokinase, the incidence rate of
cardiac rupture increased progressively from 0 .7% at 0 to 3
hto1 .2%at3to6h,1 .3%at6to9hand2 .0%at9to12h
from symptom onset (Fig. 3A). The odds ratio of cardiac
rupture (treatment/contrul) increased significantly as time to
FIgwe 2. Odds ratio of cardiac rupture in treated/control patients
versus meantime to treatment . Error bars show odds ratios and95%
confidence intervals (Cl) for the four trials with autopsies on >50%
of patients who died . The logistic regression model estimates of this
association (yr = 6.2, p = 0
.013) and its 95% confidence intervals are
displayed .
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Table 1. Few Trials Used to Assess the Effect of Thrombolytic Agents on Cardiac Rupture
Time to Treatment No. of
0 Cardiac
Autopsy
Rupture9 Odds
Mean Pa., No. Treated Ratio
9
56 71156 0.63
58 11(159
9 61 10373 0.67
52 141357
la 64 51219 2.4
65 2/207
21
60
703 3.8
67
204
ECSG = European Cooperative Study Group ; EWP = European Working Parry
; Glue = glucose; Hip =
heparin ; IVSK = intravenous streptokinese .
Fig- 1. A. Odds ratio of cardiac rupture (CR) in treatedkontrol
patients versus mean time to treatment in the G1SSI trial
(77). Error
bars show odds ratios and 95% confidence intervals (Cl) for each
time interval
. The logistic regression model estimates of this asso-
ciation ()e = 4.6, p = 0.032) and its 95% confidence intervals are
displayed. B, Odds ratio of death from cardiac rupture or electro-
mechanical dissociation (EMD) in treated/control patients versus
mean time to treatment (AZ = 6 .7, p = 0.010).
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treatment was delayed (XI = 4.6, p = 0.032), with a bensfi-
cial effect estimated for treatment within 5 h .
It has been suggested (81) that deaths from electrome-
chanical dissociation in the setting of acute myocardial
infarction should be attributed to cardiac rupture. If fatalities
from electromechanical dissociation in the GISSI trial
(37,77) were attributed to cardiac rupture, then the detrimen-
tal effect of delay in treatment would persist (32 = 6.7, p =
0.010) (Fig. 3B). Deaths from cardiac rupture or electrome-
chanical dissociation were reported (77) in 3 .0% of control
patients and in 1.8%, 3 .0%, 3.9% and 4 .7%, respectively, of
patients treated with streptokinase from 0 to 3, 3 to 6, 6 to 9
and 9 to 12 h after symptom onset.
Timing of thrombolytic therapy and sill-cause mortality. In
the 42 trials (4,8-17,37-41,48-76) pooled to assess this
effect, intravenous streptokinase was used in 19 trials
(34,896 patients), intracoronary streptokinase in 6 (568 pa-
tients), intravenous plus intracoronary streptokinase in 1
(533 patients), intravenous tissue-type plasminogen activator
in 6 (6,211 patients), intravenous anisoylated plasminogen-
streptokinase activator complex in 8 (1,960 patients) and
intravenous urokinase in 2 (178 patients). Results from nine
of the trials could be further divided into 32 subgroups by
time to treatment
. The mean time to treatment for the 65
trials or trial subgroups ranged from 0.7 to 22 h (Table 2) .
The odds ratio
for all-cause mortality (Fig . 4) was directly
correlated with time to treatment in the pooled studies ()? =
7 .6, p = 0.006)
. The odds ratio did not reach 1
.0 until 21 h
after symptom onset, and the associated 95% confidence
limits were <1 .0 for treatment given before 14 h. Whether
the mortality rate is actually increased by treatment given
_•21 h after symptom onset could not be assessed because
there were no data beyond this point . When this analysis was
repeated for each of the thrombolytic agents individually,
the time dependence of their effect on mortality was not
si fnificantly different from that noted for the overall group.
Discussion
This study suggests that the risk of cardiac rupture after
myocardial infarction is directly related to the timing of
thrombolytic therapy and that early treatment decreases the
risk of cardiac rupture, whereas late treatment increases the
risk of this complication
. The analysis confirms that the
beneficial effect of thrombolytic therapy on survival dimin-
ishes as treatment is delayed (3,37-40), but it also suggests
that this benefit persists much longer than 6 h after symptom
onset (38,47).
Cardiac rupture
. Myocardial rupture occurs in regions of
completely transmural myocardial necrosis (2,19-21), ust ;
aly
after extensive hemorrhagic transformation of the acute
infarct (21) .
The hemorrhagic transformation is usually con-
tained within the central region of necrosis where ischemia
has been severe enough to cause necrosis of the microvas-
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culature (22,23,27,82-84). Myocardial hemorrhage that re-
sults in cardiac rupture begins either at the endocardial
surface or within the myocardium and dissects through the
infarct zone to the epicardial surface (21,34,36,44). Myocar-
dial hemorrhage has been more severe among patients given
thrombolytic therapy (10,25-33), especially if treatment has
been delayed (10,33) or if the infarct has become transmural
(84) . Pathologic observations (10,24-27) from the 254 re-
ported cases (3-18,24-27,37,38,48-50,77,85-105) of cardiac
rupture after thrombolytic therapy describe transmural,
massively hemorrhagic infarcts .
The pathophysiology of cardiac rupture after myocardial
infarction suggests that eat :y thombotytic therapy might
prevent cardiac rupture by limiting the proportion of patients
whose condition progresses to transmural infarction (Fig . 1) .
Conversely, late thrombolytic therapy might allow extensive
necrosis of the myocardium and its sustaining microvascu-
lature, such that initiation of a thrombolytic state could then
lead to transmural hemorrhagic dissection and cardiac rup-
ture.
Both the mete-analysis (Fig. 2) and data from the GISSI
trial (37,77) (Fig. 3) independently demonstrate a direct
relation of the risk of cardiac rupture to the timing of
thrombolytic therapy . Both suggest that very early treatment
is beneficial and that late treatment promotes cardiac rup-
ture, but the estimates of the time course of these effects
remain somewhat imprecise.
Previous studies. Previous reviews (47,90) of the effect of
thrombolytic therapy on cardiac rupture did not examine the
effect of time to treatment and failed to account for the poor
and variable autopsy rates in most of the studies . Vasito-
manolakis et al. (90) reviewed the results of two placebo-
controlled trials (8,11), noted that rupture occurred in 10 of
41 deaths in the streptokinase-treated groups compared with
6 of 37 deaths in placebo-treated patients and suggested that
streptokinase predisposes to cardiac rupture . Yusuf et al .
(47) pooled the results of 33 randomized controlled trials of
thrombolytic agents for acute myocardial infarction and
found that the cases of cardiac rupture were equally divided
between the treated and control groups
. These investigators
(47) concluded that thrombolytic therapy had no effect on
the risk of cardiac rupture .
Mortality. Recent large studies (15,16,37,38) have varied
estimates of how long after symptom onset thrombolytic
therapy may be beneficial . Mesa-analysis has been proposed
(43) as a method for resolving uncertainties in the estimation
of treatment effects when similarly designed clinical trials
are available for data pooling . Our analysis of the results of
42 clinical trials of thrombolytic therapy according to the
time to treatment suggests that the mortality rate may be
diminished by treatment later than the conventional time
window of 4 to 6 It after symptom onset, Although these
estimates are imprecise, the 95% confidence limits of the
odds ratio are <l
.0 for treatment within 14 h of sympi m
1ACC Vol. 16. No. 2
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Figure 4. Odds ratio of death in treated/control patients versus
mean time to treatment . Error bars show odds ratios and 95%
confidence intervals (CI) for the 65 trials as combined by Mantel-
Haenseel statistics to form I I subgroups by time to treatment
. The
logistic regression model estimates of this association
(dz = 7
.6, p =
0
.006) and its 95% confidence intervals are displayed,
onset, and the regression line did not reach an odds ratio of
1 .0 until 21 h. This analysis suggests that randomized trials
of late thrmbolytis would be worthwhile to establish di-
rectly the time limit for benefit of treatment on survival .
Our analysis suggests the existence of a
time
window
daring which all-cause mortality is decreased by throm-
botytic therapy, but in which the risk of cardiac rupture is
increased. The regression line of the odds ratio for cardiac
rupture was >1
.0 for treatment given >1I h after symptom
onset (Fig. 2), whereas the regression line
of the odds ratio
for mortality did not reach 1
.0 until 21 h after symptom
onset
(Fig. 4). Although these exact time
limits are somewhat
imprecise, our analysis suggests that extending the time
window for ahrombolytic therapy may increase the number
of deaths due to cardiac rupture and still decrease the overall
mortality rate.
Limitations
. Meta-analysis continues to grow in popular-
ity as a way to resolve uncertainty about clinical questions
addressed in published reports, but the method has an
inherent weakness of using only summary data from pooled
studies. Our analysis of both cardiac rupture and mortality
used the average time to treatment for groups of patients
rather than for individual patients . This grouping impairs the
precision with which the effect of time on risk can be
estimated. However, data available from individual trials
grouped by time intervals from symptom onset to treatment
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are concordant with the results of both the cardiac rupture
and mortality analyses (3,37-41,77) .
The similar autopsy rates between treated and control
groups and among four selected trials (Table 1) suggest that
a reporting bias in the cardiac rupture rates in these studies
was not likely to have been responsible for the demonstrated
effects
. These data suggest that late thrombolysis increased
the risk of cardiac rupture ; however, as shown in Table 1,
each of these trials used aa smaller initial loading dose and
longer Infusion of streptokinase than are generally used now
.
The low initial doses may have been insufficient to halt the
transmuted progression of infarction by failing to achieve
reperfusion, and the prolonged infusions may have increased
the risk of intramural hemorrhage and, secondarily, cardiac
rupture . Data from the GISSI trial (37,77) (Fig . 3) suggest,
however, that even the briefer high dose infusions of strep
tokinase now used may promote cardiac rupture when used
late after symptom onset
.
Finally, these findings may not be applicable to other
means of coronary reperfusion such as angioplasty, which
has not been associated with the same degree of myocardial
hemorrhage as occurs after thrombolytic therapy (27) .
Clinical implications . Use of thrmbolytic agents in the
United States has largely been limited to patients
in whom
therapy can be initiated within the first 4 to 6 h of the onset
of symptoms of myocardial infarction (106). Some of the
benefit of early treatment appears to be
mediated through
prevention of cardiac rupture
. Our analysis suggests that
a
decrease in the overall mortality rate may be achievable
even if therapy is administered considerably later than 6 h
after onset of pain. Forthcoming data from several ongoing
randomized controlled trials should help to further define the
time window for benefit from "late" thrombolytic therapy .
Our analysis also suggests, however, that the overall sur-
vival benefits of later therapy may be associated with an
increased risk of cardiac rupture . Vigilance for this compli-
catico should be heightened if thrombolytic therapy is given
late after myocardial infarction because successful treatment
of cardiac rupture is possible with prompt pericardiocentesis
and surgical repair (79,97,105,107-109) .
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